Albhaisi, Somaya
Sanyal, Arun J.
Article History
First Online: 8 October 2019
Compliance with Ethical Standards
:
: The authors declare no funding information.
: Dr Albhaisi has no conflicts of interest. Dr Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, Exalenz, and Hemoshear. He has served as a consultant to AstraZeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Lilly, Poxel, Artham, Cymabay, Boehringer Ingelheim, Novo Nordisk, Bird Rock Bio, Novartis, Pfizer, Jannsen, and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Afimmune, ChemomAb, Nordic Bioscience, and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, AstraZeneca, Mallinckrodt, Cumberland, and Novartis. He receives royalties from Elsevier and UptoDate.